The Peritoneum: What Nuclear Radiologists Need to Know

Bermo, Mohammed; Koppula, Bhasker R.; Kumar, Meena; Leblond, Antoine; Matesan, Manuela

doi:10.1053/j.semnuclmed.2020.04.005

Cited by 8 publications

(11 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Modalities such as CT, gadolinium-enhanced MRI, diffusionweighted MRI, MR elastography, MR spectroscopy, MR cholangiography, US, and endoscopy are all commonly used in the clinic for tumor imaging (20)(21)(22)(23)(24)(25). Clinical molecular imaging techniques for tumor detection and characterization are most developed in PET and SPECT, as more FDA-approved small molecule-or antibody-based radiotracers are available.…”

Section: Tumor Detection Current Clinical Practice and Limitationsmentioning

confidence: 99%

“…In this review, we will briefly summarize the current cancer imaging techniques used in clinical practice for cancer detection, interventions, and treatment evaluation. This will be followed by a discussion on the challenges and limitations of small lesions (MRI and US), suboptimal image resolution (PET, US, MR spectroscopy [approximately 100 mm] [26], MR cholangiography [approximately 1 mm] [27]), radiation exposure (CT, PET, SPECT), contrast agent toxicity (gadoliniumenhanced MRI), signal specificity (ie, between inflammation or atypical infection) (CT, MRI, PET) (20,(28)(29)(30)(31)(32)(33), and limited depth penetration (US [approximately 1 cm] and optical imaging [,5 mm]) (34). A known limitation of fluorine 18 ( 18 F) fluorodeoxyglucose (FDG) PET in cancer imaging is distinguishing between cancer and inflammatory processes.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities

Liu

Grodzinski

2021

Radiology: Imaging Cancer

View full text Add to dashboard Cite

Nanoparticle (NP) imaging applications have the potential to improve cancer diagnostics, therapeutics, and treatment management. In biomedical research and clinical practice, NPs can serve as labels or labeled carriers for monitoring drug delivery or serve as imaging agents for enhanced imaging contrast, as well as providing improved signal sensitivity and specificity for in vivo imaging of molecular and cellular processes. These qualities offer exciting opportunities for NP-based imaging agents to address current limitations in oncologic imaging. Despite substantial advancements in NP design and development, very few NP-based imaging agents have translated into clinics within the past 5 years. This review highlights some promising NP-enabled imaging techniques and their potential to address current clinical cancer imaging limitations. Although most examples provided herein are from the preclinical space, discussed imaging solutions could offer unique in vivo tools to solve biologic questions, improve cancer treatment effectiveness, and inspire clinical translation innovation to improve patient care.

show abstract

Section: Tumor Detection Current Clinical Practice and Limitationsmentioning

confidence: 99%

mentioning

confidence: 99%

Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities

Liu

Grodzinski

2021

Radiology: Imaging Cancer

View full text Add to dashboard Cite

show abstract

“…Christoph Berliner 1 , Kristina Boss 2 , Anke Pape 2 , Andreas Kribben 2 , Wolfgang Fendler 1 , Ken Herrmann 1…”

Section: Autorinnen/autorenunclassified

“…Das Peritoneum ermöglicht die Mobilität der intestinalen Strukturen und spielt eine Rolle beim intraabdominellen Flüssigkeitsaustausch. In diesem Zusammenhang wird das Peritoneum medizinisch auch für Dialyse eingesetzt [1]. Die Peritonealdialyse ist ein elegantes und relativ komplikationsarmes Verfahren, welches sich die hohe Permeabilität des Peritoneums zunutze macht.…”

Section: Introductionunclassified

Oldies (but Goldies): Die Peritonealszintigrafie bei Peritonealdialyse

et al. 2021

View full text Add to dashboard Cite

“…A peritoneal adhesion (PA) is a pathological fibrous band between visceral organs or between organs and the abdominal wall [ 1 , 2 ]. Surgery, trauma, chronic peritoneal inflammation, peritoneal dialysis, endometriosis, etc., can induce PA formation [ 3 , 4 , 5 , 6 , 7 ]. However, most PAs are caused by surgery [ 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Mechanisms of Peritoneal Mesothelial Cells in Peritoneal Adhesion

Wang

Guo

2022

Biomolecules

View full text Add to dashboard Cite

A peritoneal adhesion (PA) is a fibrotic tissue connecting the abdominal or visceral organs to the peritoneum. The formation of PAs can induce a variety of clinical diseases. However, there is currently no effective strategy for the prevention and treatment of PAs. Damage to peritoneal mesothelial cells (PMCs) is believed to cause PAs by promoting inflammation, fibrin deposition, and fibrosis formation. In the early stages of PA formation, PMCs undergo mesothelial–mesenchymal transition and have the ability to produce an extracellular matrix. The PMCs may transdifferentiate into myofibroblasts and accelerate the formation of PAs. Therefore, the aim of this review was to understand the mechanism of action of PMCs in PAs, and to offer a theoretical foundation for the treatment and prevention of PAs.

show abstract

The Peritoneum: What Nuclear Radiologists Need to Know

Cited by 8 publications

References 56 publications

Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities

Nanotechnology for Cancer Imaging: Advances, Challenges, and Clinical Opportunities

Oldies (but Goldies): Die Peritonealszintigrafie bei Peritonealdialyse

Mechanisms of Peritoneal Mesothelial Cells in Peritoneal Adhesion

Contact Info

Product

Resources

About